Copyright
©The Author(s) 2020.
World J Clin Cases. Sep 26, 2020; 8(18): 4022-4033
Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.4022
Published online Sep 26, 2020. doi: 10.12998/wjcc.v8.i18.4022
Figure 1 Progression-free survival (A) and overall survival (B) of each regimen in elderly patients.
FFX: FOLFIRINOX; G mono: Gemcitabine monotherapy; GA: Gemcitabine plus nab-paclitaxel.
Figure 2 Progression-free survival (A) and overall survival (B) of each regimen in very elderly patients.
FFX: FOLFIRINOX; G mono: Gemcitabine monotherapy; GA: Gemcitabine plus nab-paclitaxel.
- Citation: Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World J Clin Cases 2020; 8(18): 4022-4033
- URL: https://www.wjgnet.com/2307-8960/full/v8/i18/4022.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i18.4022